Sibionics and PharmaSens Explore New Avenues for Insulin Delivery
Sibionics presented its "See More, Act Earlier" program at the European Association for the Study of Diabetes (EASD) 2026 conference in Milan, linking continuous monitoring with future diabetes treatment.
At the European Association for the Study of Diabetes (EASD) 2026 conference in Milan, diabetes treatment company SiBionics introduced its "See More, Act Earlier" program. The initiative aims to connect continuous glucose monitoring with future automated insulin delivery systems.
Details regarding the program's technical implementation and timeline have not yet been released by the company. The collaboration with PharmaSens suggests a focus on developing solutions that enhance diabetes management through real-time data and potential future automated drug delivery.
SiBionics' objective is to advance technology that facilitates a more proactive and precise approach to diabetes care. The EASD conference serves as a venue for showcasing the latest research and technological innovations in the field of diabetes.
Three presentations related to the program focused on integrating continuous monitoring technology with future treatment strategies. Further information is expected to be disclosed at a later date.